Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus ...

Pembrolizumab plus weekly paclitaxel, with investigator-choice bevacizumab, achieved statistically significant PFS and OS improvements, addressing a high unmet need in platinum-resistant ovarian ...

The KEYNOTE-671 trial showed a 71% 36-month overall survival rate with perioperative Keytruda, compared to 64% with placebo. FDA approvals for Keytruda, Imfinzi, and Opdivo in perioperative settings ...

Merck (NYSE:MRK) reported positive Phase 3 SMART trial results for ENFLONSIA, showing protection against RSV in high risk ...

LOS ANGELES -- Patients with metastatic melanoma have faced grim prospects: the American cancer society says the five-year survival rate is only 15 percent. That started changing when the FDA approved ...

The company will now assess the available data to determine its next steps in progressing efti’s development across multiple ...

The U.S. Food and Drug Administration (FDA) on Friday approved Merck & Co Inc.’s (NYSE:MRK) Keytruda (pembrolizumab) for adult patients with resectable locally advanced head and neck squamous cell ...

Immutep and the Australian biotech’s investors have been caught off guard by the unexpected failure of its LAG-3 candidate in a phase 3 study. | Immutep and the Australian biotech’s investors have ...

At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...

Overview: Keytruda Qlex is a medicine that is used to treat many types of cancer. This medicine is given to you as an injection under your skin by a health care provider. This medicine can cause side ...